A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2016
At a glance
- Drugs Vismodegib (Primary) ; Fluconazole; Itraconazole; Rabeprazole
- Indications Basal cell cancer; Basal cell nevus syndrome; Breast cancer; Chondrosarcoma; Gastric cancer; Glioblastoma; Medulloblastoma; Pancreatic cancer; Prostate cancer; Sarcoma; Small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Genentech
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Jan 2013 New trial record